Parkland (PKI: TSX) Investor Relations Material

Overview

PerkinElmer, Inc., a global leader in providing products, services, and solutions to the diagnostics, life sciences, and applied services markets, operates through two distinct segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions division offers a broad spectrum of instruments, informatics, software, subscriptions, detection, and imaging technologies aimed at empowering scientists to make significant research breakthroughs in life sciences. Additionally, this segment offers analytical technologies, and services for its customers to understand and characterize various aspects of environmental health, including air, water, and soil. The Diagnostics division of PerkinElmer provides instruments, reagents, assay platforms, and software products for early detection of genetic disorders like pregnancy, early childhood, and infectious disease testing in the diagnostics market. The products are employed to test and screen genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and metabolic conditions. Furthermore, this segment also focuses on developing technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. PerkinElmer serves a diverse range of clients that include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company has its roots way back in 1937 and is based in Waltham, Massachusetts.